Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript
Summarize this article with:
SA Transcripts157.36K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path December 15, 2025 11:00 AM EST Company Participants Phillip Chan - CEO & DirectorPeter Mariani - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital LLC, Research Division Presentation Jason KolbertD. Boral Capital LLC, Research Division Good morning, Dr. Chan. Phil, are you ready? Phillip ChanCEO & Director Yes, whenever you are, Jason. Thank you. Jason KolbertD. Boral Capital LLC, Research Division Good. Good morning, everyone. My name is Jason Kolbert. I am the senior biotechnology analyst, really the senior health care analyst at D. Boral Capital. One of the companies that I've been following for, got to be 10, maybe even 15 years, right, Phil?, is CytoSorbents. I'm fascinated by the company in part because, believe it or not, I have a background in chromatography going back many, many years. And when Phil first introduced the concept of what he was trying to achieve, it just made really good sense. From a mechanism of action from how the product works, the idea of a chromatic graphic-like filtration just made sense. Since that time, the company has made tremendous progress with two key products, CytoSorbents or CytoSorb and DrugSorb. One of the products removes deleterious bands of cytokines from the blood, and the other one actually can remove drugs. And in the case of what CytoSorbents is focused on today, blood thinners. The company, like all microcap companies, biotech companies, in particular, has had its share of hiccups. This is brand-new science and technology. It is an ever-evolving regulatory landscape. And it makes sense for us to do a check-in with Dr. Chan and understand kind of where the company is today, what are the next key events that investors should be focused on? And how will the company navigate their